Overview

Robotic medical devices present distinct regulatory considerations because their safety and performance may depend on the interaction of mechanical components, software, control systems, and healthcare professionals. For manufacturers planning to enter the U.S. market, understanding the applicable FDA requirements early in development is essential to establishing an appropriate FDA medical device regulatory strategy. One of the first challenges is determining how the device’s intended use, technological characteristics, and level of automation influence its regulatory classification and marketing submission pathway. Manufacturers must also evaluate the evidence needed to support the device’s safety and effectiveness, including applicable performance testing, medical device software validation, risk management, human factors, and clinical data. 

Regulatory planning becomes particularly important for devices involving robotic-assisted procedures, autonomous functions, or remote teleoperation. These technologies may raise additional questions about system reliability, user interaction, operating limitations, and the consequences of unexpected device behavior. Understanding robotic medical device regulations can help manufacturers identify these considerations during product development. This webinar will examine key FDA regulatory considerations for robotic medical devices, from early development planning through premarket submission preparation. The discussion will address regulatory pathway selection, testing and documentation requirements, risk assessment, and FDA interactions. It will also explore how FDA medical device regulatory consulting can help manufacturers evaluate submission strategies, identify potential compliance gaps, and prepare for important regulatory decisions.

Areas Covered in the Session

• Determining FDA medical device classification and the appropriate regulatory pathway based on intended use and device characteristics.
• Understanding the differences between FDA 510(k) submission, De Novo, and Premarket Approval (PMA) pathways, where applicable
• .Establishing a regulatory strategy for robotic-assisted, autonomous, and remotely teleoperated medical devices.
• Identifying applicable nonclinical testing, clinical evidence, and performance evaluation requirements.
• Addressing software verification and validation, system reliability, cybersecurity, and human factors considerations.
• Evaluating device risks and developing appropriate medical device risk management documentation.
• Preparing technical documentation and labeling to support an FDA marketing submission.
• Understanding when feedback through the FDA Q-Submission Program may help resolve questions about testing plans or regulatory strategy.
• Recognizing common submission planning gaps and approaches to addressing them.
• Exploring how FDA regulatory consulting services can support product development, submission preparation, and ongoing compliance.

Why Should You Attend?

Regulatory challenges are easier to address when they are identified during product development rather than after testing has been completed or a submission has been prepared. For robotic medical device manufacturers, early decisions about intended use, device functionality, testing strategy, and regulatory pathway can influence the evidence required to support a marketing application. A key consideration is whether the planned testing and documentation adequately address the device’s intended clinical use and reasonably foreseeable risks. Depending on the technology, manufacturers may need to evaluate software performance, system failure scenarios, user interaction, communication reliability, and the role of healthcare professionals in controlling or supervising device functions. This webinar will provide a practical overview of these regulatory considerations and explain how manufacturers can approach FDA regulatory submission strategies more systematically. Participants will gain insight into identifying evidence requirements, evaluating potential regulatory gaps, and preparing for discussions with the FDA. The session will also highlight the role of FDA medical device regulatory consulting in assessing applicable requirements, reviewing submission strategies, and helping development teams address regulatory questions before they create avoidable delays or additional work.

Who Will Benefit?

This webinar is intended for:

• Medical device manufacturers developing robotic or software-driven technologies.
• Regulatory affairs and quality assurance professionals.
• Medical technology startups preparing for U.S. market entry.
• Research and development teams involved in robotic medical device development.
• Engineers responsible for software, system performance, and device verification.
• Professionals involved in clinical evaluation, nonclinical testing, and risk management.
• Companies preparing FDA marketing submissions or evaluating regulatory pathways.

• Organizations seeking FDA regulatory consulting services and medical device submission support.

Key Takeaway

A well-defined FDA medical device regulatory strategy helps robotic medical device manufacturers understand applicable FDA requirements, plan appropriate testing, and prepare evidence to support the intended use of their products. Early evaluation of regulatory pathways, risk management, technical documentation, and potential submission gaps can support more informed development decisions and better-prepared FDA submissions.